Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Black Diamond Therapeutics, Inc. (BDTX)
Sector: Healthcare; Industry: Biotechnology

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

BDTX Symbol Info by TradingView

Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-04-12 Hatzis-Schoch Brent nan Sell 4,078 $25.00 $101,950 Yes
2021-04-05 Roberts Christopher D. Chief Scientific Officer Sell 2,500 $25.54 $63,848 Yes
2021-03-12 Hatzis-Schoch Brent nan Sell 4,078 $26.36 $107,493 Yes
2021-03-03 Roberts Christopher D. Chief Scientific Officer Sell 2,500 $26.10 $65,262 Yes
2021-02-12 Hatzis-Schoch Brent nan Sell 4,078 $27.23 $111,025 Yes
2021-02-03 Roberts Christopher D. Chief Scientific Officer Sell 2,500 $25.35 $63,375 Yes
2021-01-12 Hatzis-Schoch Brent nan Sell 11,578 $34.03 $394,041 Yes
2021-01-08 Leggett Thomas Chief Financial Officer Sell 3,000 $33.94 $101,820 Yes
2021-01-04 Roberts Christopher D. Chief Scientific Officer Sell 2,500 $31.41 $78,525 Yes
2021-01-04 Epstein David M. Director Sell 12,000 $31.13 $373,505 Yes
2020-12-14 Hatzis-Schoch Brent nan Sell 4,078 $34.95 $142,522 Yes
2020-12-08 Leggett Thomas Chief Financial Officer Sell 3,000 $33.78 $101,327 Yes
2020-12-03 Roberts Christopher D. Chief Scientific Officer Sell 2,500 $32.42 $81,055 Yes
2020-12-01 Epstein David M. Director Sell 12,000 $32.71 $392,574 Yes
2020-11-30 Bolzon Bradley J PhD 10%-Owner, Director Sell 10,393 $33.15 $344,513 No
2020-11-30 Versant Venture Capital VI, L.P. 10%-Owner Sell 10,393 $33.15 $344,513 No
2020-11-19 Versant Venture Capital VI, L.P. 10%-Owner Sell 130,017 $33.01 $4,291,861 No
2020-11-19 Bolzon Bradley J PhD 10%-Owner, Director Sell 130,017 $33.01 $4,291,861 No
2020-11-18 Bolzon Bradley J PhD 10%-Owner, Director Sell 4,730 $33.05 $156,349 No
2020-11-18 Versant Venture Capital VI, L.P. 10%-Owner Sell 4,730 $33.05 $156,349 No
2020-11-16 Versant Venture Capital VI, L.P. 10%-Owner Sell 4,700 $33.74 $158,587 No
2020-11-16 Bolzon Bradley J PhD 10%-Owner, Director Sell 4,700 $33.74 $158,587 No
2020-11-12 Versant Venture Capital VI, L.P. 10%-Owner Sell 15,598 $34.15 $532,642 No
2020-11-12 Bolzon Bradley J PhD 10%-Owner, Director Sell 15,598 $34.15 $532,642 No
2020-11-11 Roberts Christopher D. Chief Scientific Officer Sell 5,000 $34.90 $174,500 Yes
2020-11-12 Hatzis-Schoch Brent nan Sell 4,078 $33.99 $138,607 Yes
2020-11-11 Versant Venture Capital VI, L.P. 10%-Owner Sell 39,583 $34.11 $1,350,354 No
2020-11-11 Bolzon Bradley J PhD 10%-Owner, Director Sell 39,583 $34.11 $1,350,354 No
2020-11-09 Leggett Thomas Chief Financial Officer Sell 3,000 $32.96 $98,892 Yes
2020-11-09 Versant Venture Capital VI, L.P. 10%-Owner Sell 9,400 $33.08 $310,949 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.